Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tenamfetamine SCHEMBL9361151 | 1.00 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Tenamfetamine SCHEMBL29392330 | 1.00 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Tenamfetamine SCHEMBL30242630 | 1.00 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Tenamfetamine SCHEMBL30904507 | 1.00 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Tenamfetamine SCHEMBL15162053 | 1.00 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Tenamfetamine SCHEMBL393456 | 1.00 | TAAR1 (1.00) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Tenamfetamine SCHEMBL30203543 | 0.98 | TAAR1 (0.97) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Tenamfetamine SCHEMBL30401290 | 0.98 | TAAR1 (0.97) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Tenamfetamine SCHEMBL5305879 | 0.98 | TAAR1 (0.97) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL22885190 | 0.89 | TAAR1 (0.81) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119998433-A | Method for producing R-MDMA | 思维医学股份有限公司 | 2025-05-13 | — | — | CN | claimed |
| EP-4615828-A2 | SYNTHESIS OF MDA OR ITS OPTICALLY ACTIVE (R)- OR (S)-MDA ISOMERS | EmpathBio, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4615828-A2 | SYNTHESIS OF MDA OR ITS OPTICALLY ACTIVE (R)- OR (S)-MDA ISOMERS | EmpathBio, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4551680-A2 | METHODS OF MANUFACTURE OF R-MDMA | Mind Medicine, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119998433-A | Method for producing R-MDMA | 思维医学股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20250090554-A1 | A METHOD OF TREATING DEPRESSION BY IMMUNE MODULATION | MYND LIFE SCIENCES INC (CA) | 2025-03-20 | — | — | US | disclosed |
| JP-2025502054-A | — | ユニヴェルシテートスピタル バーゼル | 2025-01-24 | — | — | JP | disclosed |
| CN-119013009-A | R-MDMA and S-MDMA for use in adjuvant psychological therapy | 巴塞尔大学医院 | 2024-11-22 | — | — | CN | disclosed |
| EP-4408407-A1 | ENANTIOMERIC RATIOS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE AND RELATED METABOLITES AND USES THEREOF | atai Life Sciences AG (DE) | 2024-08-07 | — | — | EP | disclosed |
| US-20240208920-A1 | SYNTHESIS OF MDA OR ITS OPTICALLY ACTIVE (R)- OR (S)-MDA ISOMERS | EMPATHBIO, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240208920-A1 | SYNTHESIS OF MDA OR ITS OPTICALLY ACTIVE (R)- OR (S)-MDA ISOMERS | EMPATHBIO, INC. | 2024-06-27 | — | — | US | disclosed |
| WO-2024102845-A3 | SYNTHESIS OF MDA OR ITS OPTICALLY ACTIVE (R)- OR (S)-MDA ISOMERS | EMPATHBIO, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024102845-A2 | SYNTHESIS OF MDA OR ITS OPTICALLY ACTIVE (R)- OR (S)-MDA ISOMERS | EMPATHBIO, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024102845-A2 | SYNTHESIS OF MDA OR ITS OPTICALLY ACTIVE (R)- OR (S)-MDA ISOMERS | EMPATHBIO, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024011067-A2 | METHODS OF MANUFACTURE OF R-MDMA | Mind Medicine, Inc. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-20230129723-A1 | ENANTIOMERIC RATIOS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE AND RELATED METABOLITES AND USES THEREOF | EMPATHBIO, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2023056472-A1 | ENANTIOMERIC RATIOS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE AND RELATED METABOLITES AND USES THEREOF | ATAI Life Sciences AG (DE) | 2023-04-06 | — | — | WO | disclosed |
| US-20230097530-A1 | ENANTIOMERIC RATIOS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE AND RELATED METABOLITES AND USES THEREOF | EMPATHBIO, INC. | 2023-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208920-A1 | SYNTHESIS OF MDA OR ITS OPTICALLY ACTIVE (R)- OR (S)-MDA ISOMERS | COMT, PNMT, DDT | TAAR1 149/4885SLC6A4 109/4885SLC6A2 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.